Background. Cervicobrachial pain (CP) is a highincidence and prevalent condition. Cervical lateral glide (CLG) is a firstline treatment of CP. There is a current lack of enough high-quality randomized controlled double-blind clinical trials that measure the effectiveness of neural tissue mobilization techniques such as the CLG and its specific effect over CP.
Introduction
Cervicobrachial pain (CP) is a high-incidence and highly prevalent, well-described disabling medical condition [1] that affects 83 per every 100,000 people in the course of their lives [1, 2] . It is described in the scientific literature as the presence of pain in the neck that radiates or refers to the arm [3] , and it is considered a common complaint in patients seeking physiotherapy management [1] [2] [3] . The economic burden associated with neck-related disorders was estimated in a 1996 study conducted in the Netherlands to be approximately 686 million US dollars per year [4] . "Considering the rising costs of health care, it is plausible that these estimates would be higher today," according to Driessen et al. [5] . Currently the specific cost related to CP is unknown.
CP gold standard diagnosis is performed through correlative pathological findings in a magnetic resonance imaging procedure [6] . Other helpful tools in the proper diagnosis of CP are the presence of positive outcomes in the Spurling, Upper Limb, and Distraction orthopedic tests and altered results in nerve electro conduction assessment [1] . The classical patterns of pain symptoms related to this condition are caused by the existence of musculoskeletal damage and neuropathic irradiation of pain due to underlying neural tissue injuries of the cervicobrachial anatomical region [3, 7, 8] . There is current evidence of pathologic nerve trunk mechano-sensitivity alterations, central sensitizing, and viscou-elastic distortion of the cervicobrachial nervous tissue during the onset of CP symptoms; this constitutes a key point in the proper treatment selection for CP and its adequate implementation [9] [10] [11] [12] [13] [14] .
Traditionally, with the exception of surgery, firstline treatment of CP is done through the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and specific physical therapy techniques such as the cervical lateral glide (CLG) neural tissue mobilization [15, 16] . CLG neural tissue mobilization is a specific form of treatment intended for CP previously described by Elvey and Hall [17] and is capable of achieving a hypoalgesic effect during the onset of CP symptoms through the activation of descending nervous system pain modulation mechanisms, changes in the biomechanical properties of the brachial plexus, and other complex physiologic interactions that are not fully understood. The CLG physical therapy technique consists of controlled movements of the cervical and brachial plexus neural tissue. The hypoalgesic effect produced by CLG is associated with an increase in neural tissue mobility, edema, inflammation, and intraneural pressure reduction, without any known side effects when applied properly, except for a momentary worsening of symptoms (the only known side effect of CLG) [1, 10, [18] [19] [20] , which is an important contrast to the wide and sometimes severe spectrum of side effects derived from NSAIDs [21] and anticonvulsant drugs [22] .
Despite the increase in scientific interest in evidencebased options to treat pain and the effect of neural tissue mobilization techniques, there is a current lack of enough high-quality randomized controlled double-blind clinical trials that measure the effectiveness of neural tissue mobilization techniques such as the CLG and its specific effect on CP. Another specific problem in the effectivity assessment of CLG in treating CP is the nonexistence of a prospective double-blind RCT that measures beyond the immediate effect of CLG in CP, whereas only and exclusively a CLG intervention was applied without being combined at some point of the investigation with other types of treatments for CP [9, 10, 18, 23, 24] . For this reason, the present study consisted of the application of a treatment protocol based on the standalone application of CLG neural tissue mobilization in a controlled double-blind clinical trial with the aim of assessing clinical effectiveness of CLG in treating CP in a time lapse of six weeks.
We tested the hypothesis that the effectiveness of the CLG technique in the treatment of CP is significantly higher (P 0.05), compared with no treatment, according to the therapeutic approach used in this research. In consequence, the absence of a significant difference (P > 0.05) in the effectiveness of the study's treatment will be considered a null hypothesis.
The aim of the present study was to assess the effect of CLG neural mobilization in treating subjects who suffer from CP, compared with the complete absence of treatment.
Method

Trial Design
This study was an interventional phase II, parallel (two arm), double-blind (subject, physical therapist outcome assessor, data analyst, internist medical doctor, and physical therapist responsible for the CLG application) randomized controlled clinical trial with an end point classification of efficacy study 1:1 allocation ratio conducted in Venezuela (at only one site). The CONSORT guidelines were followed. No changes were made in the proposed methodology because the original protocol was not changed. Subjects were assigned to one of the two groups using restricted block randomization through a block computerized randomization software (www.ran domizer.com) that assured that each block had a size of 29 participants. Valencia (Venezuela) Policlinic Center Ethics Committee(s) approved this study (code CE0072015). All participants gave written informed consent before data collection began. The trial registration was carried out at ClinicalTrials.gov (NCT02595294).
Randomization and Blinding
The randomization and allocation to trial group protocol was done through computer software randomized printed cards contained in consecutively numbered opaque sealed envelopes. Each printed card exhibited a letter that corresponded to one of the two groups. The randomization and allocation schedule was designed by the data analyst (DA), who was blinded to the intervention treatments and the tested hypothesis through concealment of information.
The sealed envelopes were then handed to the internist medical doctor (IMD), who proceeded to deliver the envelopes to the candidates according to the designed schedule. IMD was blinded to the tested hypothesis and group randomization. Subject, physical therapist (PT), and PT outcome assessor (OA) were blinded to the randomization, the group allocation, and the tested hypothesis; this blinding process was achieved by concealing the existence of a second group as well as the tested hypothesis. The DA, PT, Subject, and OA were kept blinded after the assignment to intervention. Treatment and outcome assessments were performed in different rooms and at different time points. At all times, the need for blinding was emphasized to all participants and investigators (complete staff responsible for application, data collection, and processing).
Follow-up
The primary outcome was pain intensity reported through the Numeric Rating Scale for Pain (NRSP) at baseline for both arms and one hour after the application of treatment only in the experimental arm, corresponding to intervention days 1, 15, and 30. Reliability of the NRSP was set at an interclass correlation coefficient (ICC) of 0.76 (95% confidence interval [CI] ¼ 0.51-0.87). The threshold for the minimum clinically important difference was set at 1.3 [25] ; the standard error of measure was equal to 1.02 [26] .
Secondary outcomes were the assessment of physical function involving the affected upper limb using the Quick DASH scale (assessed at baseline, corresponding to intervention session 1 and 30; Quick DASH [ICC] ¼ 0.85). The threshold for the minimum clinically important difference was set at 17.1 [27] . Ipsilateral cervical rotation (ICR) was assessed using a CROM device at baseline for both arms and one hour after the application of treatment only in the experimental arm, corresponding to intervention days 1 and 30. Test-retest reliability of measurements of cervical range of motion using the CROM was found to be good, with ICCs ranging between 0.89 and 0.98. The standard errors of measurement across the six movements ranged from 1.6 degrees to 2.8 degrees, and the minimal detectable changes across the six movements ranged from 3.6 degrees to 6.5 degrees [28] .
Participants
Subjects were recruited from a group of voluntary consecutively assisting individuals seeking treatment or assessment related to CP in the established medical center allocation that was selected to carry out the study or by referral of six other private and public medical centers. One hundred forty-seven individuals were screened from July to November 2015. The diagnostic criteria were the presence of medically diagnosed clinical signs and symptoms of CP, such as arm pain, paresthesia, or numbness in the upper limb, accompanied by a magnetic resonance imaging (MRI) corroborative finding. A total of 58 participants were recruited and divided into two groups of 29 subjects by the IMD in concordance with the randomization schedule that the DA generated. Group "C" was composed of CLG participants, and group "D" was composed of the waiting list control group participants.
All eligible participants were adults who belonged to both genders ranging from 18 to 45 years of age with a medical diagnosis of cervicobrachial pain, confirmed by MRI, and the presence of unilateral pain, paresthesia, or numbness in the neck and arm area for at least three continuous months previous to enrollment, as well as positive results in all of the following tests: Spurling, Distraction, and Upper Limb. Exclusion criteria were intake contraindication of NSAIDs and the use of any type of treatment (therapy, procedure, or drug) to relieve pain; also excluded were participants who were using anticonvulsant, antidepressant, or psychotropic medication; had vertebral instability, vertebral osteoporosis, vertebral or spine infection; and neurologic diseases of genetic, infectious, or neoplastic origin; cervical stenosis myelopathy; pregnancy; kinesiophobia; endocrine disorders and menopause; history of spine surgery; intellectual disability; severe mental illness; intoxication; severe sleep deprivation; and Alzheimer's disease. Criteria for participant removal were the presence of any exclusion criterion at the time of measurement, voluntary abandonment, or removal by decision of the present study holders.
Physical Therapists
Eligible physical therapists for the CLG application in the present study were all consenting adults who belonged to both genders ranging from 24 to 65 years of age with at least two years of experience in CLG manual therapy technique implementation. Exclusion criteria of physical therapists were the lack of at least one of the previously mentioned criteria for eligibility and the presence of any previous mental or physical diagnosed impairment. Eligible centers were all centers properly registered according to law as health care facilities and suitable for physical rehabilitation activities. Additionally, eligible centers had to be willing to supply basic materials for the application of study protocol, be located inside the state limits, and also permit the free circulation of personnel (participants and investigators) to execute the trial. Exclusion criteria of centers were the lack of at least one of the previously mentioned criteria for eligibility.
Intervention
Eligible candidates who consented to participate in the investigation were randomly allocated to receive one of the two proposed treatments. The first group, labeled group "C" (29 participants), received a nonsurgical noninvasive CLG procedure by a physical therapist (PT) with at least two years of experience in manual therapy. The CLG was applied continuously for two minutes in five consecutive applications, with one minute of rest between each two-minute CLG application.
The CLG technique was employed five days a week and distributed in a period of six weeks; this distribution of CLG application days sums a total of 30 CLG physical therapy application days across a six-week period. The CLG procedure was applied to group "C" according to previously described principles by Butler [29, 30] and Elvey and Hall [17] for treating CP and followed the CLG procedure performed and described by Allison et al. (without the reduction of symptoms) [10, 17, 29, 30 ]:
The subject was positioned in supine, the shoulder was slightly abducted with a few degrees of medial rotation, and the elbow flexed to approximately 90 such that the hands were resting at the subject's chest or abdomen. The Physiotherapist gently supported the shoulder over the acromial region with one hand while holding and supporting the head and neck. The technique involved a gentle controlled lateral glide to the contralateral side of pain in a slow oscillating manner. [7] The second group, labeled group "D" (29 participants), did not receive any type of pain-modulating treatment during a time lapse of six weeks. This was accomplished through the use of a waiting list control group (WLCG), which did not exceed the average waiting time of a public health center. In case of clinically significant worsening of CP symptoms (an increase of 1.4 points in the NRSP) [31] or any other type of health care issue related to the waiting time for CP treatment, subjects were discharged from the study and received the best medical treatment available free of charge.
Subjects could have waived being part of the CLG group or the WLCG when they desired to or in case the IMD considered their symptoms to have worsened significantly; therefore, at all moments free will of participants to stay or abandon the experiment was respected irrefutably. Participants of both groups enjoyed free continuous medical assessment by the treating physician, which guaranteed their safety during the investigation; they also enjoyed having the invitation to use a medical rehabilitation unit and having the awareness of a wider range of treatment options for CP and the opportunity to make requests and comments about their treatment.
Outcomes
Primary Outcome
The Numeric Rating Scale for Pain is an 11-point scale for patient self-reporting of pain [1, 32] ; it was employed to evaluate the presence and relief of cervicobrachial pain symptoms by a blinded PT outcomes assessor.
Secondary Outcomes
Secondary outcomes were related to individuals' physical function; for this matter, the first secondary outcome measure was the change from baseline physical function involving the affected upper limb using the Quick DASH Scale. The Disabilities of the Arm, Shoulder, and Hand (Quick DASH) Test is a self-report short questionnaire designed to measure physical function and symptoms in people with any of several musculoskeletal disorders of the upper limb [33] . The last secondary outcome measure was the change from baseline cervical ipsilateral rotation range of motion assessed in units of rotation degrees by the use of the cervical range of motion device (CROM) [34, 35] . The PT outcomes assessor assessed all secondary outcomes. No changes were made in the proposed outcomes because the original protocol was not changed.
Statistical Methods
Only data obtained from the assessments of subjects who completed the entire protocol were statistically analyzed in the present study. Results were expressed through the use of absolute frequencies, percentages, means, averages, medians, 25th and 75th percentiles, minimum values, maximum values, standard deviations, and 95% confidence intervals (CIs). The effect size of interventions was estimated through the use of Cohen's d. Both group results followed a normal distribution according to the Kolmogorov Smirnov test. Demographic parameters related to age (years of age) and sex (masculine or feminine) were statistically analyzed through estimations of means, standard deviations, absolute frequencies, and percentages. Student's t test was employed for group average comparison.
NRSP, Quick DASH, and CROM device results were expressed in average mean values and standard deviation with a 95% confidence interval. Statistical analysis of the CLG group assessment results were performed at baseline and one hour after treatment application. It is important to clarify that session 1 corresponds to intervention day 1, session 2 corresponds to intervention day 15, and session 3 corresponds to intervention day 30 regarding NRSP, Quick DASH, and the CROM device. In the control group, only baseline values of NRSP and the CROM device were considered for analysis. This investigation results were illustrated as box and whisker plot figures. Statistical processing was performed through the computer software SSPS Version 19.
Sample Size
Creative Research Systems statistics computer software was used to set the sample size. For sample size % ¼ between-session variance percentage; þ1h ¼ time lapse corresponding to one hour after baseline application of treatment assessment; CI ¼ 95% confidence interval; CLG ¼ Cervical Lateral Glide; N ¼ number of participants; One B ¼ time lapse corresponding to baseline assessment; Range IL-SL ¼ range inferior limit minus range superior limit; Session ¼ time lapse when treatment was assessed; WLCG ¼ waiting list control group. *Baseline and one hour after baseline NRSP assessment values from sessions 1, 2, and 3 corresponding to the application of CLG and its absence in a waiting list control group, mean, between-session variance, and corresponding confidence interval. determination, a 95% confidence level with a 0.95 power and a 0.05 alpha level was considered; additionally, 15% sample loss was also anticipated. Consequently, a total sample size of 58 subjects was estimated to be randomly divided in two groups of 29 subjects.
Results
Flow of Participants
Of the original 58 participants enrolled in the present study, only 52 ended the trial. Of the 29 subjects that belonged to the CLG group (Group "C"), 25 subjects completed the trial: Three subjects abandoned participation claiming personal reasons, and one subject was removed from the study because of pain medication intake during protocol. In the WLCG (Group "D"), two participants of the initial 29 decided to abandon the study claiming personal reasons (Table 1) . No important side effects were reported related to the CLG treatment or the waiting time to receive treatment ( Figure 1 ).
Primary Outcome
The pain reduction effect reported in the CLG group NRSP mean value results were significantly (P < 0.0001) superior to those obtained by the WLCG at assessment sessions 1 and 2 of the performed assessments (corresponding to assessments performed on days 15 and 30) (Figure 2 ). Subjects treated with CLG reported a decrease of 2.16 NRSP points at the moment of discharge, which represents a 35.5% variation improvement. WLCG statistical analysis revealed an absence of intragroup NRSP diminution (Table 2) .
Secondary Outcomes
CROM device outcome values ( Figure 3 ) reported a significant (P < 0.0001) increase in the ICR only in the CLG group. The CLG group CROM device values increased an average of 10.82 degrees of cervical rotation; meanwhile no significant differences were observed in the WLCG (P ! 0.05) ( Table 3 ). Responses to the Quick DASH instrument in the WLCG did not yield any significant change in results from the baseline value, which clearly contrasted to the highly significant Quick DASH outcome (P < 0.0001) reported in the CLG group ( Figure 4 ). The CLG group reported a 34.5% Quick DASH punctuation decrease, compared with only 0.09% reported in the control group. These results revealed the positive effect of CLG in increasing function of the affected upper limb in subjects who suffer CP according to the Quick DASH instrument criteria (Table 4) .
Effect Size
Cohen's d was applied using the statistical online software from the Polytechnic University of Hong Kong (www.polyu.ed.hk) to evaluate the effect size of the CLG treatment and its absence in the control group. Results reported a small intragroup effect of pain reduction in sessions 1 and 2 (NRSP) of the CLG group (corresponding to assessment days 1 and 15, respectively). Nevertheless, a very large effect (d ¼ 2.013) was shown when the NRSP values of session 1 were compared with those reported in session 3 (assessment day 30). Cohen's d values obtained for the CLG effect size regarding the CROM device ND Quick DASH were considered to be large in session 1 and very large in session 2. WLCG Cohen's d results were considered irrelevant in session 1 and also reported small negative effects that were observed in the NRSP, CROM, and Quick DASH assessments in sessions 2 and 3 (Table 5 ).
Discussion
Results of this study clearly reveal that the proposed hypothesis was considered to be true. Therefore, CLG neural mobilization was superior to the absence of treatment in a waiting list control group composed of subjects who suffer from CP according to the applied protocol. The control group showed no significant clinical or statistical (P < 0.05) changes. without any evidence of important side effects resulting from the application [18] . The Quick DASH score reductions achieved during this investigation showed an important increase in functionality of the affected upper limb. Our Quick DASH results were in qualitative concordance to the improvement of functionality reflected in the Ellis and Hing [24] neural mobilization trial. It is important to clarify that a specific quantitative comparison of the present investigations' Quick DASH results was not possible due to the lack (according to the authors' best knowledge) of publications that employed the Quick DASH questionnaire in the assessment of the CLG treatment effect on CP. CROM Device outcomes presented less than 6 degrees of ICR variation in relation to those reported by Cowell and Phillips [36] during their investigation centered on the effect of CLG treatment in CP. This small difference of CROM Device results that favored Cowell and Phillips [36] results is possibly explained by the mixed combination of treatments performed during their study.
Effectiveness values regarding NRSP and Quick
The CLG NRSP outcomes at the moment of subject discharge of the present study are believed to be of clinical importance according to Farrar et al. [37] and are correlative to the pain reduction values (!2 points) reported by Coppieters et al. [19, 20] , Cleland et al.
[1], Allison et al. [10] , and Nee et al. [18] . It was also observed that the results of the present study behaved similarly to those presented in Cowell and Phillips [36] , where a constant reduction of pain symptoms, function improvement of the affected upper limb, and ICR increase were reported throughout the CLG treatment of CP. Because of the novelty of the applied methodology and protocol, there was no available scientific literature that could be used to compare specific parameters. All the available studies that applied CLG in CP had a mixed combination of CLG with other types of treatments in the same group of subjects, with the exception of two investigations published by Coppieters et al. in 2003 [19,20] .
It is important to mention that although both of the Coppieters et al. [19, 20] studies are related to CLG, they differed substantially with the present investigation's end point efficacy assessment, inclusion criteria, type of control group, type of CLG technique, and time frame of the % ¼ between-session variance percentage; þ1h ¼ time lapse corresponding to one hour after baseline application of treatment assessment; CI ¼ 95% confidence interval; CLG ¼ Cervical Lateral Glide; N ¼ number of participants; One B ¼ time lapse corresponding to baseline assessment; Range IL-SL ¼ range inferior limit minus range superior limit; Session ¼ time lapse when treatment was assessed; WLCG ¼ waiting list control group. *Session 1 and 2 baseline assessment and one hour after baseline CROM device assessment values corresponding to the application of CLG and its absence in a waiting list control group, mean, between-session variance, and corresponding confidence interval.
reported outcomes. For these reasons, the authors of the present study will not further discuss any more details about the mentioned studies performed by Coppieters et al.; nevertheless, these investigations into NRSP reduction of result are in concordance with those reported in both of the Coppieters et al. [19, 20] investigations.
Our results lead us to believe that CP is a multidimensional condition where joint and neuorogenic pain may coexist and overlap as proposed by Zamorano [38] , Allison et al. [10] , and Elvey and Hall [17] . This strong interrelation among musculoskeletal and nervous tissue may explain the effectivity of a CLG treatment in subjects with CP where both musculoskeletal and nervous tissue dysfunction are present [19] . This argument is supported by the fact that CLG treatment is not specific to the neural targeted tissue [17, 38] ; therefore, indirect joint mobilization of the neck could have posed an indirect benefit in the treatment of CP [10, 17, 38] . The findings support that the CLG treatment had a direct impact in CP by reducing peripheral and central neurogenic pain perception, which is extensively known to be a source of local inflammation and nociception [12] . This rationale is consistent with Santos et al.'s [39] histological and Western blot findings, which suggested that neurogenic and peripheral inflammation activated through dorsal horn sensitizing of glial cells are reversible by the application of neural mobilization and antiinflammatory treatment [39] .
A constant limitation faced during this investigation was the lack of prior high-quality research related to CLG and neural mobilization in CP. Continuous statements made by the scientific community related to the low quality of previous research included the lack of sufficiently narrow inclusion criteria, a large enough sample size, homogenous CLG technique, and the use of a no-treatment control group. In consideration of this fact, the authors of the present study made an additional effort in solving methodological problems reported in previous CLG research that negatively affected the already scarcely available literature.
Sources of potential bias were found in the primary outcome and the participant blinding method. We believe that the NRSP results of this study cannot be used to determine whether pain was of neurogenic or musculoskeletal inflammatory origin; nevertheless, special care was taken in the inclusion criteria of participants to assure that pain of neural origin was also present. Blinding of participants was an additional challenge; for this matter, study hypothesis, control group's existence, and group allocation blinding were the method of choice for subject masking, which is considered according to Boutron et al. [40] an effective blinding procedure. Therefore, the study holders considered that blinding was achieved successfully. Due to the lack of dipper subgroup analysis and additional reproductions of the applied protocol, the authors considered the generalization of the study results to be impossible.
Other possible sources of bias were the PT opinions on CLG effectiveness in CP and the existence of therapeutic alliance between the PT and the treated subject. In the current study, extensive data on PT opinions on the applied CLG treatment were not collected, nor were the PT behaviors or interpersonal skills; for these reasons, the present study holders could not explore how these factors affect patients' ratings or results derived from the CLG treatment. It is also possible that the therapeutic alliance favored the positive CLG treatment outcome exhibited during the present study. Previous research performed by Hall et al. [41] highlighted that the "patient-therapist relationship may influence treatment effects" [41] . The Hall et al. [41] refereed study states the nonexistence of specifically validated procedures to measure this concept in physical therapy treatments. Considering the absence of a specific validated tool for measuring therapeutic alliance in physical therapy research, the level of therapeutic alliance was not investigated in the present physical therapy study.
Conclusion
CLG is superior to the absence of treatment in reducing pain and increasing the affected upper limb function of subjects who suffer CP. CLG may be considered an effective treatment in specific cases of CP.
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